glp 1 on medicaid US states drop coverage of GLP-1 weight-loss drugs as demand rises | US healthcare The evolving landscape of anti-obesity

The recent positive topline results from Eli Lilly and Company 's ATTAIN-MAINTAIN trial for orforglipron, however, signal a potential paradigm shift

Further LEfSe analysis showed that Lactobacillus and Bifidobacterium played an essential role in regulating intestinal microbiota diversity

And they follow a recent blow from a clinical trial on GLP-1s and Parkinsons disease that similarly showed drug treatment didnt seem to help

Cost-effectiveness insights are crucial as these drugs move toward broader clinical adoption.

Speak with your health-care professional if you have used an unauthorized GLP-1 product and have concerns about your health